Zachary Thomas Herbert, M.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sequence Analysis, RNA | 3 | 2020 | 2012 | 0.860 |
Why?
|
| Gene Library | 3 | 2020 | 1074 | 0.760 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 3597 | 0.720 |
Why?
|
| RNA, Ribosomal | 1 | 2018 | 246 | 0.580 |
Why?
|
| Tuberous Sclerosis | 3 | 2023 | 1029 | 0.350 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2023 | 450 | 0.330 |
Why?
|
| Carboplatin | 2 | 2021 | 801 | 0.280 |
Why?
|
| MicroRNAs | 1 | 2020 | 3752 | 0.240 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2021 | 86 | 0.200 |
Why?
|
| Facial Neoplasms | 1 | 2022 | 121 | 0.200 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2022 | 2104 | 0.190 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 3586 | 0.190 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2019 | 31 | 0.180 |
Why?
|
| Histone Demethylases | 2 | 2019 | 321 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 4803 | 0.170 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2019 | 30 | 0.170 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2022 | 294 | 0.170 |
Why?
|
| Neuroendocrine Cells | 1 | 2019 | 61 | 0.170 |
Why?
|
| Triterpenes | 1 | 2019 | 80 | 0.160 |
Why?
|
| Telomerase | 1 | 2023 | 730 | 0.160 |
Why?
|
| Angiomyolipoma | 1 | 2020 | 190 | 0.160 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2018 | 134 | 0.160 |
Why?
|
| Poly A | 1 | 2018 | 185 | 0.160 |
Why?
|
| Phospholipase D | 1 | 2017 | 70 | 0.150 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 783 | 0.150 |
Why?
|
| Enteroendocrine Cells | 1 | 2017 | 65 | 0.140 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 351 | 0.140 |
Why?
|
| Immunity | 2 | 2022 | 1012 | 0.140 |
Why?
|
| Cell Dedifferentiation | 1 | 2017 | 135 | 0.140 |
Why?
|
| Epigenomics | 2 | 2019 | 903 | 0.140 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 319 | 0.140 |
Why?
|
| Autoantigens | 1 | 2020 | 892 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2023 | 2849 | 0.130 |
Why?
|
| Ovarian Neoplasms | 2 | 2023 | 4838 | 0.130 |
Why?
|
| Anti-Obesity Agents | 1 | 2019 | 217 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 388 | 0.130 |
Why?
|
| Receptors, Notch | 1 | 2019 | 739 | 0.130 |
Why?
|
| Software | 2 | 2020 | 4443 | 0.130 |
Why?
|
| Astrocytoma | 1 | 2019 | 790 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2015 | 380 | 0.120 |
Why?
|
| Astrocytes | 1 | 2022 | 1270 | 0.120 |
Why?
|
| Interleukin-17 | 1 | 2020 | 899 | 0.120 |
Why?
|
| Duodenum | 1 | 2017 | 483 | 0.120 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 428 | 0.120 |
Why?
|
| Histones | 3 | 2019 | 2599 | 0.120 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 618 | 0.120 |
Why?
|
| Imidazoles | 1 | 2020 | 1206 | 0.120 |
Why?
|
| Autoimmunity | 1 | 2021 | 1349 | 0.120 |
Why?
|
| Myeloid Cells | 1 | 2018 | 810 | 0.110 |
Why?
|
| Signal Transduction | 7 | 2021 | 23403 | 0.110 |
Why?
|
| Workflow | 1 | 2018 | 847 | 0.110 |
Why?
|
| Cytokines | 3 | 2022 | 7322 | 0.110 |
Why?
|
| Mice | 16 | 2023 | 81183 | 0.110 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 972 | 0.110 |
Why?
|
| RNA Splicing | 1 | 2017 | 907 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2018 | 1189 | 0.110 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2024 | 1736 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 594 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 4262 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 1341 | 0.110 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 851 | 0.100 |
Why?
|
| Intestine, Small | 1 | 2018 | 1241 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 1838 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 4386 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3557 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2022 | 2988 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 2529 | 0.100 |
Why?
|
| Mice, Knockout | 6 | 2022 | 14557 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 1678 | 0.100 |
Why?
|
| Leptin | 1 | 2019 | 1599 | 0.090 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 1878 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2023 | 8428 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2023 | 2282 | 0.090 |
Why?
|
| HEK293 Cells | 4 | 2021 | 4204 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 1222 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 2133 | 0.090 |
Why?
|
| Animals | 18 | 2023 | 168757 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 2043 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1788 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 4479 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3703 | 0.080 |
Why?
|
| Cell Differentiation | 3 | 2021 | 11483 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2020 | 2942 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2022 | 3336 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2021 | 13033 | 0.080 |
Why?
|
| Leukemia | 1 | 2016 | 1511 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 9438 | 0.070 |
Why?
|
| Oxygen | 1 | 2019 | 4189 | 0.070 |
Why?
|
| Chromatin | 1 | 2019 | 2934 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2023 | 11124 | 0.070 |
Why?
|
| Lymphoma | 1 | 2016 | 1877 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2023 | 16689 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2023 | 4217 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 3523 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2021 | 2716 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 5181 | 0.070 |
Why?
|
| Genomics | 1 | 2021 | 5720 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2019 | 4286 | 0.060 |
Why?
|
| Humans | 26 | 2024 | 744343 | 0.060 |
Why?
|
| Stem Cells | 1 | 2017 | 3567 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 5853 | 0.060 |
Why?
|
| HIV-1 | 1 | 2021 | 6939 | 0.060 |
Why?
|
| Cell Proliferation | 4 | 2021 | 10481 | 0.060 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2024 | 140 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 3143 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 13695 | 0.050 |
Why?
|
| Inflammation | 2 | 2021 | 10638 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 19905 | 0.050 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2021 | 78 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 6314 | 0.050 |
Why?
|
| Base Pair Mismatch | 1 | 2021 | 97 | 0.050 |
Why?
|
| Kidney | 1 | 2017 | 7186 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2023 | 12208 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5256 | 0.050 |
Why?
|
| Homeodomain Proteins | 2 | 2023 | 2421 | 0.050 |
Why?
|
| Templates, Genetic | 1 | 2020 | 211 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 270 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 2942 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 481 | 0.040 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2019 | 37 | 0.040 |
Why?
|
| Nucleotides | 1 | 2022 | 464 | 0.040 |
Why?
|
| Virus Latency | 1 | 2021 | 358 | 0.040 |
Why?
|
| Arginine | 1 | 2022 | 944 | 0.040 |
Why?
|
| Serine | 1 | 2022 | 826 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2019 | 198 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 8863 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 644 | 0.040 |
Why?
|
| Sphingosine | 1 | 2020 | 307 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2020 | 566 | 0.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2019 | 182 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2020 | 331 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2020 | 844 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2019 | 297 | 0.040 |
Why?
|
| Virus Internalization | 1 | 2021 | 501 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 18029 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2023 | 1058 | 0.040 |
Why?
|
| DNA | 2 | 2021 | 7301 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2024 | 1821 | 0.040 |
Why?
|
| Receptor, trkA | 1 | 2017 | 164 | 0.040 |
Why?
|
| Obesity | 1 | 2019 | 12745 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 1179 | 0.040 |
Why?
|
| Genome, Bacterial | 1 | 2021 | 760 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2020 | 805 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 1465 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 675 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 2187 | 0.030 |
Why?
|
| Methylation | 1 | 2019 | 1106 | 0.030 |
Why?
|
| Androgens | 1 | 2023 | 1281 | 0.030 |
Why?
|
| Oncogenes | 1 | 2022 | 1265 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
| Oligodendroglia | 1 | 2019 | 517 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2022 | 838 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 1613 | 0.030 |
Why?
|
| HIV Infections | 1 | 2021 | 16718 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 1377 | 0.030 |
Why?
|
| Benchmarking | 1 | 2021 | 1042 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 5172 | 0.030 |
Why?
|
| Apoptosis | 2 | 2021 | 9727 | 0.030 |
Why?
|
| Histone Code | 1 | 2015 | 163 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 402 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 367 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2019 | 1285 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 222 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2017 | 10252 | 0.030 |
Why?
|
| Mutation | 3 | 2023 | 29786 | 0.030 |
Why?
|
| Female | 10 | 2023 | 380194 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 2077 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13102 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 666 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 2938 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2021 | 1809 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 907 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 1114 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 380 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2018 | 2256 | 0.030 |
Why?
|
| Virus Replication | 1 | 2021 | 2534 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2021 | 2440 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1477 | 0.030 |
Why?
|
| Synapses | 1 | 2022 | 1728 | 0.030 |
Why?
|
| Phenotype | 2 | 2023 | 16365 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 1526 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
| Immune System | 1 | 2017 | 805 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2018 | 3689 | 0.030 |
Why?
|
| DNA Damage | 1 | 2021 | 2432 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 2429 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 1581 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2020 | 2258 | 0.020 |
Why?
|
| Cell Communication | 1 | 2018 | 1621 | 0.020 |
Why?
|
| Microglia | 1 | 2019 | 1266 | 0.020 |
Why?
|
| Neutrophils | 1 | 2023 | 3719 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2018 | 2715 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 20822 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2017 | 1538 | 0.020 |
Why?
|
| Folic Acid | 1 | 2017 | 1300 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2018 | 3002 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 2924 | 0.020 |
Why?
|
| Male | 8 | 2023 | 350118 | 0.020 |
Why?
|
| Fibrosis | 1 | 2017 | 2029 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 21827 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 1741 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2017 | 2263 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3616 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 1790 | 0.020 |
Why?
|
| Proteomics | 1 | 2021 | 3638 | 0.020 |
Why?
|
| Genome, Human | 1 | 2021 | 4420 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 3505 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4751 | 0.020 |
Why?
|
| Cell Movement | 1 | 2020 | 5217 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2018 | 4026 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 3617 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 2494 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2016 | 2504 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2018 | 3086 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 4740 | 0.020 |
Why?
|
| Prognosis | 2 | 2017 | 29063 | 0.020 |
Why?
|
| Base Sequence | 1 | 2018 | 12797 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 6895 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4851 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2017 | 2149 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1799 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 4256 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2488 | 0.020 |
Why?
|
| Macrophages | 1 | 2020 | 5655 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 15997 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 9734 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 17446 | 0.020 |
Why?
|
| Alleles | 1 | 2015 | 6933 | 0.020 |
Why?
|
| Internet | 1 | 2016 | 3064 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13284 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 12072 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 11031 | 0.010 |
Why?
|
| Neurons | 1 | 2022 | 9338 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 10180 | 0.010 |
Why?
|
| Diet | 1 | 2019 | 7939 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 5987 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 9648 | 0.010 |
Why?
|
| Time Factors | 1 | 2018 | 40075 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11524 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12261 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 15519 | 0.010 |
Why?
|
| Aged | 2 | 2018 | 163280 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 40561 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 213383 | 0.010 |
Why?
|
| Adult | 2 | 2018 | 214055 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 57776 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 77449 | 0.010 |
Why?
|